Trisodium nitrilotriacetate

257.08

256.988831

225-768-6

E3C8R2M0XD

1240

DTXSID8027587

2921199090

124

-2.62 (calculated)

DryPowder; Liquid; OtherSolid

0.56

69-71 °C(lit.)

498.2ºC at 760mmHg

255.1ºC

H2O: insoluble

Keep containers tightly sealed. Store in a cool dry area. Take precautionary measures against static discharges. Ensure all storage areas are well ventilated.

LD50 oral in rat: 1100mg/kg

Dust explosion possible if in powder or granular form, mixed with air.

NONH for all modes of transport

2

22-40-36

36-46-36/37-26

MB8400000

Xn

Separated from strong oxidants and strong acids. Well closed.

P301 + P312 + P330-P305 + P351 + P338

H302-H319-H351

SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational harm/injury/toxicity or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal and plant life; and conformance with environmental and public health regulations.

DHEW/NCI; Bioassays of Nitrilotriacetic Acid (NTA) and Nitrilotriacetic Acid, Trisodium Salt, Monohydrate for Possible Carcinogenicity (1977) Technical Rpt Series No. 6 DHEW Pub No. (NIH) 77-806

Combustible under specific conditions. Gives off irritating or toxic fumes (or gases) in a fire. Finely dispersed particles form explosive mixtures in air.

|Warning|H302: Harmful if swallowed [Warning Acute toxicity, oral]|P201, P202, P264, P270, P280, P281, P301+P312, P305+P351+P338, P308+P313, P330, P337+P313, P405, and P501|H302 (98.49%): Harmful if swallowed [Warning Acute toxicity, oral]|Aggregated GHS information provided by 1325 companies from 16 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.|P201, P202, P260, P264, P270, P280, P281, P301+P312, P305+P351+P338, P308+P313, P309+P311, P314, P330, P337+P313, P405, and P501

In case of fire in the surroundings, use appropriate extinguishing media.

/NIOSH approved respirator/; rubber gloves; chemical safety goggles.

SRP: The scientific literature for the use of contact lenses by industrial workers is inconsistent. The benefits or detrimental effects of wearing contact lenses depend not only upon the substance, but also on factors including the form of the substance, characteristics and duration of the exposure, the uses of other eye protection equipment, and the hygiene of the lenses. However, there may be individual substances whose irritating or corrosive properties are such that the wearing of contact lenses would be harmful to the eye. In those specific cases, contact lenses should not be worn. In any event, the usual eye protection equipment should be worn even when contact lenses are in place.

Dust /is/ irritating to eyes, nose and throat. ... Solid /is/ irritating to skin and eyes.

Personal protection: chemical protection suit including self-contained breathing apparatus. Do NOT let this chemical enter the environment. Sweep spilled substance into covered containers. If appropriate, moisten first to prevent dusting. Carefully collect remainder. Then store and dispose of according to local regulations.

Separated from strong oxidants and strong acids. Well closed.

No indication can be given about the rate at which a harmful concentration of this substance in the air is reached on evaporation at 20 °C.

The substance is corrosive to the eyes, skin and respiratory tract. Corrosive on ingestion.

This substance is possibly carcinogenic to humans.

NO open flames. Closed system, dust explosion-proof electrical equipment and lighting. Prevent deposition of dust.

PREVENT DISPERSION OF DUST! STRICT HYGIENE!

Use local exhaust or breathing protection.

Protective gloves. Protective clothing.

Wear safety goggles or face shield.

The development of renal tumors was examined in rats given 1000 ppm N-ethyl-N-hydroxyethylnitrosamine (NEELA) and then 30,000, 10,000 or 3,000 ppm of trisodium nitrilotriacetate monohydrate (Na3 X NTA X H20) in their food. The incidences of renal tumors in rats treated with N-ethyl-N-hydroxyethylnitrosamine for 2 wk and then 30,000, 10,000 and 3,000 ppm trisodium nitrilotriacetate monohydrate for 30 wk were 100, 86 and 22%, respectively, while they were 16 and 0% in rats treated with N-ethyl-N-hydroxyethylnitrosamine or 30,000 ppm trisodium nitrilotracetate monohydrate at 30,000 or 10,000, but not 3,000 ppm, also incr the size and number of renal tumors in rats treated with N-ethyl-N-hydroxyethylnitrosamine and trisodium nitrilotriacetate monohydrate 30,000 ppm, but not 10,000 or 3,000 ppm also induced hydronephrosis in rats irrespective of whether they were treated with N-ethyl-N-hydroxyethylnitrosamine. Thus, trisodium nitrilotriacetate monohydrate has a dose-related effect on the kidney. /Trisodium nitrilotriacetate monohydrate/|ORAL ADMIN OF TRISODIUM NITRILOTRIACETATE (0.01, 0.10, OR 1% WT/VOL IN DRINKING WATER) DID NOT ENHANCE THE PATHOLOGICAL EFFECTS OF LEAD ON THE RAT RENAL SYSTEM; HOWEVER, RATS GIVEN 0.01 OR 0.10% WITH OR WITHOUT LEAD WERE HYPERGLYCEMIC.|The effects of the renal tumor promoters; beta-cyclodextrin, DL-serine, basic lead acetate, trisodium nitrilotriacetate monohydrate & potassium bromate, & diethylene glycol as a negative control, on early stage of renal carcinogenesis were investigated in unilaterally nephrectomized male Wistar rats after N-ethyl-N-hydroxyethylnitrosamine admin. Wistar male rats were fed 1000 ppm N-ethyl-N-hydroxyethylnitrosamine diet for 2 wk & the left kidney was removed at week 3, then the animals were divided into 7 groups of 15 rats each. These groups received the following treatments: 1000 ppm lead acetate, 10000 ppm trisodium nitrilotriacetatemonohydrate or 500 ppm potassium bromate diet for 18 wk from wk 3; 45 mg/100 g bw/day of beta-cyclodextrin injected sc for 7 days; 100 mg/100 g bw of DL-Serine injected sc biweekly for 6 weeks; 5% diethylene glycol in drinking water as a negative control for two days. Five rats in each group were killed at wk 8, 12 & 20 & their kidneys were examined histologically. At wk 20, the avg numbers of adenomatous hyperplasias seen as preneoplastic lesions in the beta-C, DL-Serine, lead acetate, trisodium nitrilotriacetate monohydrate or potassium bromate groups were significantly higher than those in the diethylene glycol or control groups. Thus within a relatively short period of 20 wk, promoting effects of chemicals can be detected as a significant incr of adenomatous hyperplasias in this model. /Trisodium nitrilotriacetate monohydrate/|The dose-dependent effect of trisodium nitrilotriacetate monohydrate as a promoter in two stage carcinogenesis in the urinary bladder of male Wistar rats was investigated. Carcinogenesis was initiated by administration of 0.05% N-butyl-N-(4-hydroxybutyl)nitrosamine in the drinking water for 4 weeks, then trisodium nitrilotriacetate monohydrate was given at 1%, 0.5% and 0.3% in the diet for 28 weeks, and rats were killed in week 32. The incidences and numbers of preneoplastic lesions (papillary or nodular hyperplasia, PN hyperplasia) in rats treated with 0.3% to 1% trisodium nitrilotriacetate monohydrate increased progressively with increasing concentration of trisodium nitrilotriacetate monohydrate. The incidences of papillomas in rats treated with 1% and 0.5% trisodium nitrilotriacetate monohydrate in the diet and the incidence of transitional cell carcinoma of the urinary bladder in the rats treated with 1% trisodium nitrilotriacetate monohydrate (P< 0.05) were significantly higher than those in rats treated with N-butyl-N-(4-hydroxybutyl)nitrosamine only. Administration of various doses of trisodium nitrilotriacetate monohydrate without N-butyl-N-(-hydroxybutyl)nitrosamine did not cause any histological changes (papillary or nodular hyperplasia, papilloma or transitional cell carcinoma) in the urinary bladder. These findings showed that trisodium nitrilotriacetate monohydrate is a potent promoter of urinary bladder carcinogenesis initiated by N-butyl-N-(4-hydroxybutyl)nitrosamine in rats, and that its effect is dose-dependent. /Trisodium nitrilotriacetate monohydrate/|For more Interactions (Complete) data for TRISODIUM NITRILOTRIACETATE (9 total), please visit the HSDB record page.

LC50 Mouse ip 680 mg/kg bw|LD50 Mouse ip 300 mg/kg bw|LD50 Rat ip 254-444 mg/kg bw|LC50 Rat inhalation >5 mg/L /4 hr|For more Non-Human Toxicity Values (Complete) data for TRISODIUM NITRILOTRIACETATE (15 total), please visit the HSDB record page.

/OTHER TERRESTRIAL SPECIES/ Studies on 4 succeeding generations of the snail Helisoma trivolvis indicated that nominal concentrations up to 100 mg/L were not acutely toxic. Concentrations above 25 mg/L imposed a stress on growth and fecundity of snails.

According to the 2006 TSCA Inventory Update Reporting data, the number of persons reasonably likely to be exposed in the industrial manufacturing, processing, and use of trisodium nitrilotriacetate is 100 to 999; the data may be greatly underestimated(1).

Chemicals that bind to and remove ions from solutions. Many chelating agents function through the formation of COORDINATION COMPLEXES with METALS. (See all compounds classified as Chelating Agents.)

TRISODIUM AMINOTRIACETATE WAS WELL ABSORBED IN RATS AND DOGS, & EXCRETED UNCHANGED IN URINE. THE AMT (8 UG/G BONE), WHICH WAS INCORPORATED INTO RAT SKELETON IN COMBINATION WITH CA2+ REPRESENTED ONLY 0.007% OF THE 24 HR TURNOVER OF CALCIUM IN THAT TISSUE, AND WAS CONSIDERED UNLIKELY TO AFFECT DEVELOPMENT ADVERSELY.|RATS WERE GIVEN TRISODIUM NITRILOTRIACETATE AT DIETARY LEVELS OF 0.05, 0.1, 0.3, 0.5, 0.75, OR 2% FOR 42 & 30 DAYS. NITRILOTRIACETATE DID NOT ACCUMULATE IN BLADDER TISSUES TO ANY GREATER EXTENT THAN IN HEART AND LIVER, EVEN WHEN URINARY NTA LEVELS WERE EQUAL TO OR GREATER THAN 200 TIMES THOSE IN PLASMA.|In a whole body autoradiographic study, 0.93 Mg (1-(14)C-acetate) NTA, trisodium salt was administered intravenously to NMRI albino mice and the same amount orally to C57BI mice; heavy accumulation of radioactivity occurred in the skeleton, which persisted for 48 h, the longest interval studied.

Fresh air, rest. Half-upright position. Artificial respiration may be needed. Refer for medical attention.

Remove contaminated clothes. Rinse skin with plenty of water or shower.

First rinse with plenty of water for several minutes (remove contact lenses if easily possible), then refer for medical attention.

/SRP:/ Immediate first aid: Ensure that adequate decontamination has been carried out. If patient is not breathing, start artificial respiration, preferably with a demand valve resuscitator, bag-valve-mask device, or pocket mask, as trained. Perform CPR if necessary. Immediately flush contaminated eyes with gently flowing water. Do not induce vomiting. If vomiting occurs, lean patient forward or place on the left side (head-down position, if possible) to maintain an open airway and prevent aspiration. Keep patient quiet and maintain normal body temperature. Obtain medical attention. /Poisons A and B/|/SRP:/ Basic treatment: Establish a patent airway (oropharyngeal or nasopharyngeal airway, if needed). Suction if necessary. Watch for signs of respiratory insufficiency and assist ventilations if needed. Administer oxygen by nonrebreather mask at 10 to 15 L/min. Monitor for pulmonary edema and treat if necessary ... . Monitor for shock and treat if necessary ... . Anticipate seizures and treat if necessary ... . For eye contamination, flush eyes immediately with water. Irrigate each eye continuously with 0.9% saline (NS) during transport ... . Do not use emetics. For ingestion, rinse mouth and administer 5 mL/kg up to 200 mL of water for dilution if the patient can swallow, has a strong gag reflex, and does not drool ... . Cover skin burns with dry sterile dressings after decontamination ... . /Poisons A and B/|/SRP:/ Advanced treatment: Consider orotracheal or nasotracheal intubation for airway control in the patient who is unconscious, has severe pulmonary edema, or is in severe respiratory distress. Positive-pressure ventilation techniques with a bag valve mask device may be beneficial. Consider drug therapy for pulmonary edema ... . Consider administering a beta agonist such as albuterol for severe bronchospasm ... . Monitor cardiac rhythm and treat arrhythmias as necessary ... . Start IV administration of D5W /SRP: "To keep open", minimal flow rate/. Use 0.9% saline (NS) or lactated Ringer's if signs of hypovolemia are present. For hypotension with signs of hypovolemia, administer fluid cautiously. Watch for signs of fluid overload ... . Treat seizures with diazepam or lorazepam ... . Use proparacaine hydrochloride to assist eye irrigation ... . /Poisons A and B/

/SIGNS AND SYMPTOMS/ NO SENSITIZATION OR ADVERSE SKIN IRRITATION WAS PRESENT IN HUMANS AFTER TOPICAL APPLICATION OF TRISODIUM NITRILOTRIACETATE OR PRODUCTS CONTAINING TRISODIUM NITRILOTRIACETATE.

Acid, Nitrilotriacetic

The substance can be absorbed into the body by inhalation of its aerosol and by ingestion.

Burning sensation. Sore throat. Cough. Laboured breathing. Shortness of breath.

Redness. Skin burns. Pain.

Redness. Pain. Severe deep burns.

Available commercially as pure solid or as a solution in water.

All other basic organic chemical manufacturing|Glycine, N,N-bis(carboxymethyl)-, sodium salt (1:3): ACTIVE|TRISODIUM SALT OF NITRILOTRIACETIC ACID HAS BEEN TESTED AND FOUND EFFECTIVE IN BINDING COPPER AND ZINC.|TRISODIUM SALT OF NTA WAS PROPOSED AS A SUBSTITUTE FOR PHOSPHATE IN DETERGENTS.

TRISODIUM NITRILOTRIACETIC ACID IN THE PRESENCE OF OTHER CARBOXYLIC ACIDS WAS DETERMINED BY GAS CHROMATOGRAPHY.|EMSLC Method 430.1, NTA (Colorimetric, Manual, Zinc-Zincon). Colorometric, detection limit = 0.5 mg/L|EMSLC Method 430.2, NTA (Colorimetric, Automated, Zinc-Zincon). Colorometric, detection limit = 0.040 mg/L

Cosmetics -> Chelating